Company: LGN
Filing Date: 2025-11-03
Form Type: DRS
Source: 0001193125-25-262782
Chunk: 123

Company: Legence Corp.
Filing Date: 2025-11-03
Form: DRS
Chunk 123
---
 issued and sold 29,487,627 shares of our Class A Common Stock at a public offering price of $28.00 per share. We received net proceeds of approximately $780.2 million from sales of shares of Class A Common Stock in the IPO, after deducting underwriting discounts and commissions. We indirectly contributed all of the net proceeds from the IPO to Legence Holdings in exchange for LGN Units that were issued to Legence Sub. Legence Holdings used approximately $773.0 million of the net proceeds from the IPO to repay amounts outstanding under the Term Loan Credit Facility. A portion of the proceeds was used to pay fees and expenses in connection with the IPO. The remaining net proceeds were used for general corporate purposes. To date, our primary uses of capital have included funding working capital, capital expenditures for equipment used in our business, acquisitions and refinancing or repayment of debt and associated interest. Although our capital expenditures have historically been low relative to our revenues, we expect an increase in future periods due to our investment in fabrication capacity expansion within our Installation & Maintenance segment. 84

Confidential Treatment Requested by Legence Corp. Pursuant to 17 C.F.R. Section 200.83 Although we cannot provide any assurance that our cash flows from operations will be sufficient to fund our operations or that additional capital will be available to us on acceptable terms, or at all, we believe our primary sources of liquidity are sufficient to fund our ongoing working capital, investing and financing requirements for at least the next twelve months and beyond. In the event that we require additional capital, we may seek to raise funds at any time through equity, equity-linked arrangements and debt. If we are unable to raise additional capital when desired and on reasonable terms, our business, results of operations, and financial condition would be adversely affected. See the section titled “Risk Factors” for additional information. Cash Flows The information presented below was derived from our Condensed Consolidated Statements of Cash Flows within the Condensed Consolidated Financial Statements and the Consolidated Statements of Cash Flows within the Consolidated Financial Statements and summarizes cash flow activity (dollars in thousands):

| Cash provided by (used in):                               |     | Six Months Ended 
 June 30,         
 2024             |         |   |     | 2025 |         |   |
|:----------------------------------------------------------|:----|:-----------------|--------:|:--|:----|:-----|--------:|:--|
| Operating activities                                      |     | $